Mibefradil
This unique calcium channel blocker selectively blocks T-type calcium channels (in addition to L-type channels), which had potential advantages in treating heart disease and hypertension. It was withdrawn from the market shortly after approval because it caused dangerous interactions with many commonly used medications by inhibiting liver enzymes that metabolize drugs.
Moleküler Ağırlık
495,6000 g/mol
LogP
5,80
TPSA
67,50 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
2D Yapı
Cite this structure
Embed this structure
SMILES
COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C
InChI
InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
Molecular Formula
C29H38FN3O3
HBD / HBA
1 / 6
Döndürülebilir Bağlar
12
Ağır Atomlar
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This unique calcium channel blocker selectively blocks T-type calcium channels (in addition to L-type channels), which had potential advantages in treating heart disease and hypertension. It was withdrawn from the market shortly after approval because it caused dangerous interactions with many commonly used medications by inhibiting liver enzymes that metabolize drugs.
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Yes, Mibefradil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL45816. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60663. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="mibefradil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/mibefradil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/mibefradil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/mibefradil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="mibefradil"></drugfyi-drug>